The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report

The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report

ES评分 0 浏览量：1059 下载量：0

DOI	10.20900/jpbs.20190001
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2019, 4(1)
作者	Mary R. Lee*,Heidi J. Wehring,Robert P. McMahon,Fang Liu,Jared Linthicum,Robert W. Buchanan,Gregory P. Strauss,Leah H. Rubin,Deanna L. Kelly,
作者单位	1 Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 21228, USA; 2 Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore MD 21201, USA; 3 Women’s Mental Health Research Program, University of Illinois at Chicago, IL 60612, USA
Abstract	Social cognition is impaired in patients with schizophrenia and is related to functional outcome. Neither current pharmacologic treatments for psychotic symptoms nor psychosocial interventions robustly improves measures of social cognition. Given this, the development of adjunctive treatments to improve functional outcome is a rational approach to treatment research in schizophrenia. The neuropeptide oxytocin is a candidate to treat deficits in social cognition due to its prosocial as well as anxiolytic effects. We report here results from a randomized, double-blind, parallel group 3 week clinical trial with daily administration of adjunctive intranasal oxytocin (20 IU twice daily) (n = 13) or placebo (n = 15). We examined the effect of oxytocin administration on measures of 4 domains of social cognition, as well as social functioning. After 3 weeks of oxytocin/placebo dosing, there was no significant difference favoring oxytocin between treatment groups in any outcome measure. These results add to the body of literature examining the effects of oxytocin on social cognition in schizophrenia. Further study is warranted.
KeyWord	oxytocin; schizophrenia; social cognition
基金项目
页码	-

参考文献
相关文献

1.Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nat Rev Neurosci. 2015;16(10):620-31.

2.Couture SM, Roberts DL, Penn DL, Cather C, Otto MW, Goff D. Do baseline client characteristics predict the therapeutic alliance in the treatment of schizophrenia? J Nerv Mental Dis. 2006;194(1):10-4.

3.Addington J, Saeedi H, Addington D. Influence of social perception and social knowledge on cognitive and social functioning in early psychosis. Br J Psychiatry 2006;189:373-8.

4.Brekke J, Kay DD, Lee KS, Green MF. Biosocial pathways to functional outcome in schizophrenia. Schizophr Res. 2005;80(2-3):213-25.

5.Sergi MJ, Rassovsky Y, Nuechterlein KH, Green MF. Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am J Psychiatry. 2006;163(3):448-54.

6.Vauth R, Rusch N, Wirtz M, Corrigan PW. Does social cognition influence the relation between neurocognitive deficits and vocational functioning in schizophrenia? Psychiatry Res. 2004;128(2):155-65.

7.Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Hormones Behav. 2012;61(3):392-9.

8.Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12(9):524-38.

9.Goldman M, Marlow-O'Connor M, Torres I, Carter CS. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res. 2008;98(1-3):247-55.

10.Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res. 2010;124(1-3):13-21.

11.Rubin LH, Carter CS, Drogos L, Jamadar R, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia. Schizophr Res. 2011;130(1-3):266-70.

12.Walss-Bass C, Fernandes JM, Roberts DL, Service H, Velligan D. Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia. Schizophr Res. 2013;147(2-3):387-92.

13.Strauss GP, Keller WR, Koenig JI, Gold JM, Frost KH, Buchanan RW. Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. Schizophr Res. 2015;162(1-3):47-51.

14.Strauss GP, Keller WR, Koenig JI, Sullivan SK, Gold JM, Buchanan RW. Endogenous oxytocin levels are associated with the perception of emotion in dynamic body expressions in schizophrenia. Schizophr Res. 2015;162(1-3):52-56.

15.Brown EC, Tas C, Kuzu D, Esen-Danaci A, Roelofs K, Brune M. Social approach and avoidance behaviour for negative emotions is modulated by endogenous oxytocin and paranoia in schizophrenia. Psychiatry Res. 2014;219(3):436-42.

16.Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Drogos LL, Hill SK, et al. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull. 2014;40(6):1374-84.

17.Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Harris MS, Hill SK, Reilly JL, Sweeney JA. Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophr Res. 2013;146(1-3):138-43.

18.Keri S, Kiss I, Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc Neurosci. 2009;4(4):287-293.

19.Oya K, Matsuda Y, Matsunaga S, Kishi T, Iwata N. Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. 2016;266(5):439-50. doi:10.1007/s00406-015-0634-9.

20.Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, et al. A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr Bull. 2015;41(2):483-93.

21.Davis MC, Horan WP, Nurmi EL, Rizzo S, Li W, Sugar CA, Green MF. Associations between oxytocin receptor genotypes and social cognitive performance in individuals with schizophrenia. Schizophr Res. 2014;159(2-3):353-7.

22.Gibson CM, Penn DL, Smedley KL, Leserman J, Elliott T, Pedersen CA. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr Res. Jul 2014;156(2-3):261-5.

23.Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B. et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010;68(7):678-80.

24.Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011;132(1):50-3.

25.Lee MR, Wehring HJ, McMahon RP, Linthicum, J, Cascella, N, Liu, F, et al. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res. 2013;145(1-3):110-5.

26.Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 2013;27(1):57-65.

27.Jarskog LF, Pedersen CA, Johnson JL, Hamer RM, Rau SW, Elliott T, Penn DL. A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia. Schizophr Res. 2017;185:88-95.

28.Buchanan RW, Kelly DL, Weiner E, Gold JM, Strauss GP, Koola MM, McMahon RP, Carpenter WT. A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia. J Clin Psychopharmacol. 2017;37(4):394-400.

29.Bürkner P-C, Williams DR, Simmons TC, Woolley JD. Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis. Schizophr Bull. 2017;43(6):1291-303.

30.Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry. 2003;54(12):1389-98.

31.Uvnas-Moberg K, Petersson M. Oxytocin, a mediator of anti-stress, well-being, social interaction, growth and healing. Z Psychosom Med Psychother. 2005;51(1):57-80.

32.Acheson D, Feifel D, de Wilde S, McKinney R, Lohr J, Risbrough V. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology. 2013;229(1):199-208.

33.First MB. The DSM series and experience with DSM-IV. Psychopathology. 2002;35(2-3):67-71.

34.DeRenzo EG, Conley RR, Love R. Assessment of capacity to give consent to research participation: state-of-the-art and beyond. J Health Care Law Policy. 1998;1(1):66-87.

35.Mayer JD, Salovey P, Caruso DR, Sitarenios G. Measuring emotional intelligence with the MSCEIT V2.0. Emotion. 2003;3(1):97-105.

36.Bellack AS, Brown CH, Thomas-Lohrman S. Psychometric characteristics of role-play assessments of social skill in schizophrenia. Behav Ther. 2006;37(4):339-52.

37.Kee KS, Horan WP, Salovey P, Kern RS, Sergi MJ, Fiske AP, et al. Emotional intelligence in schizophrenia. Schizophr Res. 2009;107(1):61-8.

38.Frajo-Apor B, Pardeller S, Kemmler G, Welte A-S, Hofer A. Emotional Intelligence deficits in schizophrenia: The impact of non-social cognition. Schizophr Res. 2016;172(1-3):131-6.

39.DeTore NR, Mueser KT, McGurk SR. What does the Managing Emotions branch of the MSCEIT add to the MATRICS consensus cognitive battery? Schizophr Res. 2018;doi:10.1016/j.schres.2018.02.018.

40.Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5-19.

41.Kerr SL, Neale JM. Emotion perception in schizophrenia: specific deficit or further evidence of generalized poor performance? J Abnorm Psychol. 1993;102(2):312-8.

42.Ambady N, Hallahan M, Rosenthal R: On judging and being judged accurately in zero-acquaintance situations. J Pers Soc Psychol 1995;69:519–29.

43.Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323-29.

44.Tennen H, Herzberger S, Nelson HF. Depressive attributional style: the role of self-esteem. J Pers. 1987;55(4):631-60.

45.Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-6.

46.Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001;42(2):241-51.

47.Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther. 1998;36(4):455-70.

48.Watson D, Friend R. Measurement of social-evaluative anxiety. J Consult Clin Psychol. 1969;33(4):448-57.

49.Davis MC, Green MF, Lee J, Horan WP, Senturk D, Clarke AD, Marder SR. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology. 2014;39(9):2070-2077.

50.Davis MC, Lee J, Horan WP, Clarke AD, McGee MR, Green MF, Marder SR. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res. 2013;147(2-3):393-7.

51.Abu-Akel A, Fischer-Shofty M, Levkovitz Y, Decety J, Shamay-Tsoory S. The role of oxytocin in empathy to the pain of conflictual out-group members among patients with schizophrenia. Psychol Med. 2014;44(16):3523-32.

52.Fischer-Shofty M, Shamay-Tsoory S, Levkovitz Y. Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls. Front Neurosci. 2013;7(127). doi:10.3389/fnins.2013.00127.

53.Burkner PC, Williams DR, Simmons TC, Woolley JD. Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis. Schizophr bull. 2017;43(6):1291-303.

54.Williams DR, Burkner PC. Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis. Psychoneuroendocrinology. 2017;75:141-51.

55.Michalopoulou P, Wigton R, Averbeck B, Shergill S. M67. The Neural Effects of Oxytocin on Social Decision-Making in Schizophrenia: An fMRI Study. Schizophr Bull. 2017;43(Suppl 1): S234.

56.Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci. 2011;15(7):301-9.

57.Granholm E, Holden J, Worley M. Improvement in Negative Symptoms and Functioning in Cognitive-Behavioral Social Skills Training for Schizophrenia: Mediation by Defeatist Performance Attitudes and Asocial Beliefs. Schizophr Bull. 2018 Apr 6;44(3):653-61. doi:10.1093/schbul/sbx099.

58.Uhrig S, Hirth N, Broccoli L, von Wilmsdorff M, Bauer M, Sommer C, et al. Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study. Schizophr Res. 2016;177(1-3):59-66.

59.Jurek B, Neumann ID. The Oxytocin Receptor: From Intracellular Signaling to Behavior. Physiol. Rev. 2018;98(3):1805-908.

引用本文

Mary R. Lee*,Heidi J. Wehring,Robert P. McMahon,Fang Liu,Jared Linthicum,Robert W. Buchanan,Gregory P. Strauss,Leah H. Rubin,Deanna L. Kelly. The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report, Journal of Psychiatry and Brain Science. 2019; 4; (1). https://doi.org/10.20900/jpbs.20190001.

文献评论

相关学者

相关机构